WRF
TXG icon

Waddell & Reed Financial’s 10x Genomics TXG Stock Holding History

Waddell & Reed Financial’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$89M Buy
491,857
+127,078
+35% +$21.9M 0.18% 156
2020
Q4 		$51.7M Sell
364,779
-642
-0.2% -$93.2K 0.11% 223
2020
Q3 		$45.6M Sell
365,421
-3,771
-1% -$396K 0.11% 213
2020
Q2 		$33M Buy
369,192
+556
+0.2% +$43.3K 0.09% 253
2020
Q1 		$23M Buy
368,636
+249,583
+210% +$19.5M 0.07% 268
2019
Q4 		$9.08M Sell
119,053
-5,898
-5% -$355K 0.02% 397
2019
Q3 		$6.3M Buy
+124,951
New +$6.91M 0.02% 411

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $151M AUM 26.94% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Waddell & Reed Financial's TXG Position: Q1 2021 in Review

Waddell & Reed Financial increased its 10x Genomics (TXG) stake by 35% in Q1 2021, buying an estimated $21.9M and bringing the position to 491,857 shares worth $89M. The position accounts for 0.18% of the portfolio, ranked #156.

Waddell & Reed Financial first reported a position in TXG in Q3 2019 and has held it in 7 quarters since. 324 funds tracked by Wall St. Rank hold TXG as of Q1 2021.

  • Waddell & Reed Financial held 491,857 shares of 10x Genomics worth $89M as of Q1 2021.
  • Waddell & Reed Financial bought 127,078 10x Genomics shares in Q1 2021, an estimated $21.9M.
  • 10x Genomics made up 0.18% of Waddell & Reed Financial's portfolio in Q1 2021, its #156 holding.
  • Waddell & Reed Financial first reported a position in 10x Genomics in Q3 2019 and has held it in 7 quarters since.
  • 324 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.